Why the study?
Do CYP2C19 polymorphisms predict platelet aggregation response to clopidogrel in Thai patients with cardiovascular disease?
Population
1,051 Thai patients for prevalence analysis, including a subset of 96 cardiovascular disease patients on 75…
Design
Cross-sectional
Authors
Loading...
CYP2C19 poor metabolizer status was associated with clopidogrel non-response in Thai patients; extends evidence to this population but leaves clinical utility open.
Do CYP2C19 polymorphisms predict platelet aggregation response to clopidogrel in Thai patients with cardiovascular disease?
In a Thai population, CYP2C19 poor metabolizer variants are highly prevalent and significantly associated with a lack of platelet inhibition response to clopidogrel.
Sukasem et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: